Brasília – Brazil’s medicinal cannabis market is entering a new phase of growth and consolidation, marked by lower prices, expanding patient demand and the prospect of updated regulations. Manufacturers have recently reduced the prices of cannabidiol (CBD) products by 30% to 40%, seeking to make treatments more accessible and strengthen their position in a competitive and still-evolving market.

The current regulatory framework, established by Anvisa’s Resolution RDC 327/2019, is expected to undergo revision soon. Starting in 2025, companies will need to renew five-year authorizations and may be required to present clinical study plans and pursue full drug registration. Proposed changes could also expand the permitted forms of administration and allow pharmacies to compound and dispense CBD-based products directly, significantly increasing access for patients.

Despite these advances, challenges remain. The market continues to depend heavily on imported raw materials, faces high operational costs, and still lacks a national policy for research and domestic production. Experts point out that sustained regulatory clarity, local innovation incentives and broader public awareness are essential for ensuring equitable access to cannabis-based therapies in Brazil’s healthcare system.

Source: Futuro da Saúde

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com